Hubungan antara Pola Resistensi OAT Lini Pertama dan Gradasi Gambaran Foto Toraks Penderita TB Paru MDR
[First-Line Antituberculosis Drugs Resistance and Chest X-Ray Pattern of Multidrug-Resistant Tuberculosis Patient]
Downloads
Background: Tuberculosis (TB) is a disease which has long been known and is still a cause of death in the world. The emergece of the drug resistance in TB treatment, particularly Multi drug-Resistance Tuberculosis (MDR TB) become a significant public health problem in many countries. The diagnosis of MDR TB based on culture results. In some cases radiographic feature with severe abnormalities consideres as MDR TB. From this phenomenon, there is no research that connects the resistance pattern of first line ATD with chest x-ray feature in patients with MDR TB. Methods: The research design are analytical observational with cross-sectional study conducted in outpatient clinic of MDR TB in Dr. Soetomo hospital. Subjects were patients who are following a theraphy program in outpatient clinic of MDR TB in Dr. Soetomo hospital from 2012 to 2014 who meet the inclusion and exclusion criteria. A total of 65 patients. Result: the result of this study showed that of all patterns of resistance, most of the MDR TB patients were classified as having severe chest radiograph. 27 patients with RH resistance patterns, there were 14(51.9%) who had a chest radiograph are classified as severe. 5 patients with RHS resistance patterns, 2(60%) vwho had a chest radiograph are classified as severe. 13 patients RHES resistance patterns, 8(61.5%) who had a chest radiograph are classified as severe. 20 patients with RHE resistance patterns, 14(70%) who had a chest radiograph are classified as severe. Conclusion: There were no significant association between resistance pattern of first line ATD and chest x-ray feature in patient with MDR TB.
WHO Report 2011: Global Tuberculosis Control. Geneva: WHO 17.12.2012 Avaliable at http://whqlibdoc.who.int/ puplication/2011/9789241564380 eng.pdf
DITJEN PP & PL KEMENTERIAN KESEHATAN RI. Laporan situasi terkini perkembangan tuberkulosis di Indonesia Januari– Desember 2012.
World Health Organization: The Global TB-MDR and XDR Response Plan 2007–2008. WHO Library2006, pp. 2–3.
World Health Organization. Global Tuberculosis Control. WHO reports 2012. 5. Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinant of virulence. Clinical Microbiology Reviews, Juli 2003. Vol. 16, No. 3. p. 463–496.
PDPI. Tuberkulosis. Pedoman diagnosis dan penatalaksanaan di Indonesia. 2011.
Cohen T, Sommers. B, Murray. M. The effect of drug resistance on the fitness of mycobacterium tuberculosis. The Lancet Infectious Disease. Vol. 3 January 2003.
Shwartz M. Drug resistant strain of tuberculosis are more virulent than experts assumed. Avaliable at www.news.stanford.edu/news/2006/ august9/tbstudy. 080906.html.
Edward Khan A, Michael E. Chemoterapy of tuberculosis In Tuberculosis and nontuberculosis infections, edited David 5th, McGraw-Hill. USA 2006; 77–90.
Hasan H. Tuberkulosis Paru Dalam: Wibisono MJ, Winariani, Hariadi S, ed. Buku Ajar Ilmu Penyakit Paru. Edisi ke-2. Departwmen Ilmu Penyakit Paru FK Unair-RSUD Dr. Soetomo. Surabaya 2010: h. 9–30.
Roitt. Immunology. 6th ed. Mosby. New York. 2001: 1–36.
Abbas AK, Litchtman AH, Puber JS. Immunity to microbes. In: cellular and molecular immunology. 2nd ed. WE Saunders Company Philadelphia. 1994: p. 320–33.
Barnes PF, Wizel B. Type 1 cytokines and the pathogenesis of tuberculosis. A, J Respir Crit care Med. 2000; 161: 1773–4.
Baratawidjaja KG. Sitokin. Dalam: Imunologi dasar. Edisi 4. Balai penerbit FKUI. Jakarta. 2000: h. 93–105.
Iseman MD. Immunity and pathogenesis. In: Iseman MD, editor. A clinician's Guide to Tuberculosis. Lippincott Williams and Wilkins. Philadelphia. 2000: p. 63–96.
Schluger NW, Rom WN. The host immune response to tuberculosis – state of the art. Am J Respir Crit Care Med. 1998; 157: 679–91.
Tomasheki JF, Dannenberg AM. Pathogenesis of pulmonary tuberculosis. In: Fishman AP, Elias JA, Fishman JA, et al., editors. Fishman Pulmonary disease and disorders. 3rd ed. McGraw-Hill. New York. 1998: p. 2447–71.
Mattheas L, Steinmuller C, Ulliman GF. Pulmonary macrophage. Eur Respir J. 1994; 7: 1683–4.
Toews GB. Cytokines and the lung. Eur Respir J. 2001; 34: 3–175.
Brodin P. Virulence mechanism in tuberculosis. Avaliable at www. moleculartb.org/gb/pdf/transcriptions/12_P Brodin.pdf
Forrellad MA, Kleepp LI, Giofre A, et al. Virulence factors of the mycobacterium tuberculosis complex. Virulence 2013; 4(1): 1–64.
Dachlan YP. Imunologi tuberkulosis: sistem imun, pembentukan granuloma, dormanasi, reaktivasi infeksi laten MDR tuberkulosis. Dalam: Soedarsono, Widodo ADW, Hidayat B, ed. The problems of TB PARU MDRfrom basic to clinic and community. Rumah Sakit Penyakit Tropik Infeksi Universitas Airlangga. Surabaya. 2013: h. 1–16.
World Health Organization: Guidlines for the programmatic management of drug resistant tuberculosis. WHO library. 2008.
Camiero JA. Guidlines for clinical and operational management of drug resistant tuberculosis 2013. International Union Against Tuberculosis and Lung Disease.
Kemenkes RI. Strategi nasional pengendalian TB di Indonesia. 2011.
Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. The International Journal of Tuberculosis and Lung Disease 2009; 13: 1320–1330.
Petrini B, Hoffner S. Drug resistant and multidrugs resistant tubercle bacilli. International Journal Antimicrobial Agents 1999; 13: 93–7.
Chan EWC, Chan RCY, Au. MTK, Lai RWM. Physiological fitness of drug resistant mycobacterium tuberculosis isolates in Hongkong. Hongkong Med. J. 2013; 19(5): S4–7.
Borrel S, Gagneux S. infectiousness, reproductive fitness and evolution of drug resistant mycobacterium tuberculosis. Int. J. Tuberc Lung Dis. 2009. 13 (12): 1456–1466.
Gillespie SH. Evolution of drug resistance in mycobacterium tuberculosis: Clinical and molecular perspective. Antimicrob. Agents. Chemother. 2002, 46(2): 267–274.
Billington OJ, Mc Hugh TD and Gillespie SH. Physiological cost of rifampin resistance induced in vitro in mycobacterial tuberculosis. Antimicrob. Agent. Chemother. 1999, 43: 1866–1869.
Hopewill PC. Overview of clinical tuberculosis. In Bloom BR (ed), Tuberculosis: Pathogenesis, Protections and control. ASM press. Washington DC.USA 1994.
Jeong YJ, Lee KS. Pulmonary tuberculosis: up to date imaging and management. AJR 2008, 191: 834–844.
Saeed W. Cavitating pulmonary tuberculosis: a global challenge. Clinical Medicine 2012. Vol. 12 No1: 40–41.
Zahirifard S, Amiri VM, Bakhshayesh KM, et all. The radiological spectrum of pulmonary multidrug-resistant tuberculosis in HIVnegative patients. Iran J. Radiol. December 2003.
National Tuberculosis Association of USA. Diagnostic standarts and classification of tuberculosis. 1961. New York:National Tuberculosis Association.
Papathaks P, Piwoz E, Editors. Nutrition and tuberculosis: a review of the literature and consideration for tuberculosis control programs. Chapter 3, Malnutrition, immunity and tuberculosis. Washington: United status for international development. 2008. p. 11–7.
Karyadi E, Schultink W, Nelwan RH, et al. Poor miconutrient status of active pulmonary tuberculosis patients in indonesia. The Journal of Nutrient 2000.
Podewils LJ, Holtz T, Riekstore V, et al. Impact of malnutrition on clinical presentation, clinical course and mortality in multidrug resistent tuberculosis patient. Epidemiol Infect. 2011; 139(1): 113–20.
Caminero JA. Multidrug resistant tuberculosis: epidemiology, risk factors and case findings. Int. J tuberc lung disease 2010; 14(4): p. 382–90.
Subhan M, Soedarsono. Perubahan gambaran foto toraks waktu pengobatan TB paru dan saat terdiagnosa TB paru MDR. 2014.
Copyright (c) 2016 Pramanindyah Bekti Anjani, Soedarsono Soedarsono
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (